Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

March 15, 2021

Study Completion Date

March 23, 2021

Conditions
Anti-Ulcer Agents
Interventions
DRUG

coadministration of JP-1366 and aceclofenac

An open-label, multiple-dosing, fixed sequence, 3-period design

DRUG

coadministration of JP-1366 and meloxicam

An open-label, multiple-dosing, fixed sequence, 3-period design

DRUG

coadministration of JP-1366 and naproxen

An open-label, multiple-dosing, fixed sequence, 3-period design

DRUG

single-dosing of JP-1366 in Korean and Caucasian

An open-label, single-dosing, parallel design

Trial Locations (1)

Unknown

Cha University Bundang Medical Center, Gyeonggi-do

Sponsors
All Listed Sponsors
lead

Onconic Therapeutics Inc.

INDUSTRY

NCT05181124 - Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian | Biotech Hunter | Biotech Hunter